Nevirapine Plus Zidovudine to Prevent Perinatal HIV in Thailand

PHASE3CompletedINTERVENTIONAL
Enrollment

1,792

Participants

Timeline

Start Date

January 31, 2001

Study Completion Date

June 30, 2004

Conditions
HIV InfectionsPregnancy
Interventions
DRUG

Single dose nevirapine to the mother and to the child

One maternal 200 mg NVP dose at the onset of labor, and one dose of infant NVP (0.6 ml/6mg) between 48-72 hours after birth. \[Infants less than 2,500g received only 0.2mL/kg\]

DRUG

Single dose nevirapine to the mother and placebo to the child

One maternal 200 mg NVP dose at the onset of labor, and one dose of infant placebo (0.6 ml) between 48-72 hours after birth. \[Infants less than 2,500g received only 0.2mL/kg\]

DRUG

Single dose placebo to the mother and to the child

One maternal placebo dose at the onset of labor, and one dose of infant placebo (0.6 ml) between 48-72 hours after birth. \[Infants less than 2,500g received only 0.2mL/kg\]

Trial Locations (1)

50200

Phpt - Ird 174, Chiang Mai

All Listed Sponsors
collaborator

Harvard School of Public Health (HSPH)

OTHER

collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

collaborator

ANRS, Emerging Infectious Diseases

OTHER_GOV

lead

Institut de Recherche pour le Developpement

OTHER_GOV

NCT00398684 - Nevirapine Plus Zidovudine to Prevent Perinatal HIV in Thailand | Biotech Hunter | Biotech Hunter